CLARISCAN

Country: Israel

Bahasa: Inggeris

Sumber: Ministry of Health

Bahan aktif:

GADOTERIC ACID

Boleh didapati daripada:

ELDAN ELECTRONIC INSTRUMENTS CO LTD, ISRAEL

Kod ATC:

V08CA02

Borang farmaseutikal:

SOLUTION FOR INJECTION

Komposisi:

GADOTERIC ACID 279.3 MG / 1 ML

Laluan pentadbiran:

I.V

Jenis preskripsi:

Required

Dikeluarkan oleh:

GE HEALTHCARE AS, NORWAY

Kawasan terapeutik:

GADOTERIC ACID

Tanda-tanda terapeutik:

Enhancement of contrast in magnetic resonance imaging.Aencephalic and spinal pathologies: brain tumours, tumours of the spine and the surrounding tissue, intervertebral disk prolapse infectious diseases.Abdominal pathologies: primary and secondary liver tumours.Osteo-articular pathology: bone and soft tissue tumours synovial diseases.Magnetic resonance imaging for angiography.

Tarikh kebenaran:

2020-02-04

Ciri produk

_ _
_ _
1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCTS
Clariscan
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 mL of solution:
Gadoteric acid*
.......................................................................................................
279.3 mg
corresponding to gadoterate meglumine
...................................................... 376.9 mg
corresponding to gadolinium oxide
............................................................... 90.62
mg
corresponding to
tetraxetan…………………………………………………….202.46
mg
*Gadoteric acid: complex of gadolinium with
1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic
acid
Concentration in the contrast agent: 0.5 mmol/mL
For a full list the excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for I.V injection in pre-filled syringe, vial or bottles
(glass and polypropylene).
Clear, colourless to slightly yellow solution.
Osmolality: 1350 mOsm.kg
-1
Viscosity at 20°C: 3.0 mPa.s
Viscosity at 37°C: 2.1 mPa.s
pH: 6.5 to 8.0.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
•
Enhancement of contrast in magnetic resonance imaging.
•
Encephalic and spinal pathologies: brain tumours, tumours of the spine
and the surrounding tissue,
intervertebral disk prolapse infectious diseases.
•
Abdominal pathologies: primary and secondary liver tumours.
•
Osteo-articular pathology: bone and soft tissue tumours synovial
diseases.
•
Magnetic resonance imaging for angiography.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
The lowest dose that provides sufficient enhancement for diagnostic
purposes should be used.
The recommended dose is 0.1 mmol/kg, i.e., 0.2 mL/kg, in adults,
children and infants.
In angiography, depending on the results of the examination being
performed, a second injection may be
administered during the same session if necessary.
In some exceptional cases, as in the confirmation of isolated
metastasis or the detection of leptomeningeal
tumours, a second injec